{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:32:39Z","timestamp":1789450359588,"version":"build-2803163510"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To appraise all available antithrombotic treatments within or after 12 months following coronary revascularization and\/or acute coronary syndrome in two network meta-analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Forty-three (N\u00a0=\u00a0189\u00a0261 patients) trials within 12 months and 19 (N\u00a0=\u00a0139\u00a0086 patients) trials beyond 12 months were included for efficacy\/safety endpoints appraisal. Within 12 months, ticagrelor 90\u00a0mg bis in die (b.i.d.) [hazard ratio (HR), 0.66; 95% confidence interval (CI), 0.49\u20130.88], aspirin and ticagrelor 90\u00a0mg (HR, 0.85; 95% CI, 0.76\u20130.95), or aspirin, clopidogrel and rivaroxaban 2.5\u00a0mg b.i.d. (HR, 0.66; 95% CI, 0.51\u20130.86) were the only treatments associated with lower cardiovascular mortality, compared with aspirin and clopidogrel, without or with greater bleeding risk for the first and the other treatment options, respectively. Beyond 12 months, no strategy lowered mortality; compared with aspirin; the greatest reductions of myocardial infarction (MI) were found with aspirin and clopidogrel (HR, 0.68; 95% CI, 0.55\u20130.85) or P2Y12 inhibitor monotherapy (HR, 0.76; 95% CI: 0.61\u20130.95), especially ticagrelor 90\u00a0mg (HR, 0.54; 95% CI, 0.32\u20130.92), and of stroke with VKA (HR, 0.56; 95% CI, 0.44\u20130.76) or aspirin and rivaroxaban 2.5\u00a0mg (HR, 0.58; 95% CI, 0.44\u20130.76). All treatments increased bleeding except P2Y12 monotherapy, compared with aspirin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Within 12 months, ticagrelor 90\u00a0mg monotherapy was the only treatment associated with lower mortality, without bleeding risk trade-off compared with aspirin and clopidogrel. Beyond 12 months, P2Y12 monotherapy, especially ticagrelor 90\u00a0mg, was associated with lower MI without bleeding trade-off; aspirin and rivaroxaban 2.5\u00a0mg most effectively reduced stroke, with a more acceptable bleeding risk than VKA, compared with aspirin.<\/jats:p>\n                    <jats:p>Registration URL: https:\/\/www.crd.york.ac.uk\/PROSPERO\/; Unique identifiers: CRD42021243985 and CRD42021252398.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvad016","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T18:12:18Z","timestamp":1677694338000},"page":"271-290","source":"Crossref","is-referenced-by-count":37,"title":["Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC)"],"prefix":"10.1093","volume":"9","author":[{"given":"Eliano Pio","family":"Navarese","sequence":"first","affiliation":[{"name":"Department of Cardiology and Internal Medicine, Nicolaus Copernicus University , Bydgoszcz ,","place":["Poland"]},{"name":"SIRIO MEDICINE Research Network ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-1083","authenticated-orcid":false,"given":"Antonio","family":"Landi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale , Via Tesserete 48, 6900 Lugano ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Oliva","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20090 Pieve Emanuele, Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Piccolo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Division of Cardiology, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-9818","authenticated-orcid":false,"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dupuytren University Hospital, and INSERM 1094 & IRD, University of Limoges , 2, Martin Luther King ave, 87042, Limoges ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Florida College of Medicine-Jacksonville , 655 West 8th Street, Jacksonville, FL 32209,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Atar","sequence":"additional","affiliation":[{"name":"Oslo University Hospital Ulleval, Department of Cardiology, and Institute of Clinical Medicine, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-7723","authenticated-orcid":false,"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero Universitaria Policlinico \u2018G. Rodolico-San Marco\u2019, University of Catania , Via Santa Sofia, 78, Catania 95123,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A A","family":"Fox","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular Science, University of Edinburgh Division of Clinical and Surgical Sciences ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Blindern, P.O. Box 1078, N-0316 , Oslo ,","place":["Norway"]},{"name":"Department of Cardiology, Oslo University Hospital Ulleval , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"James","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala University , Uppsala 75185,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-0670","authenticated-orcid":false,"given":"Peter","family":"J\u00fcni","sequence":"additional","affiliation":[{"name":"Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2975-6971","authenticated-orcid":false,"given":"Vijay","family":"Kunadian","sequence":"additional","affiliation":[{"name":"Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2447-7685","authenticated-orcid":false,"given":"Sergio","family":"Leonardi","sequence":"additional","affiliation":[{"name":"University of Pavia and Coronary Care Unit, Fondazione IRCCS Policlinico San Matteo , Pavia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[{"name":"The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[{"name":"ACTION Group, INSERM UMRS 1166, Institut de Cardiologie, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Assistance Publique-H\u00f4pitaux de Paris, Sorbonne Universit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Niebauer","sequence":"additional","affiliation":[{"name":"Institute of Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical University Salzburg , 5020 Salzburg ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6425-3360","authenticated-orcid":false,"given":"Susanna","family":"Price","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, National Heart and Lung Institute, Imperial College , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6677-6229","authenticated-orcid":false,"given":"Robert F","family":"Storey","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield , Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"V\u00f6ller","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Faculty of Health Science Brandenburg, University of Potsdam , Potsdam ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1526-0652","authenticated-orcid":false,"given":"Pascal","family":"Vranckx","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis , Hasselt ,","place":["Belgium"]},{"name":"Faculty of Medicine and Life Sciences, Hasselt University , Hasselt ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4488-1335","authenticated-orcid":false,"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4353-7110","authenticated-orcid":false,"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale , Via Tesserete 48, 6900 Lugano ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"2026080909323061500_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080909323061500_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"2026080909323061500_bib3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080909323061500_bib4","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/eurheartj\/ehv038","article-title":"Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial","volume":"36","author":"Costa","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080909323061500_bib5","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"key":"2026080909323061500_bib6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026080909323061500_bib7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080909323061500_bib8","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"2026080909323061500_bib9","first-page":"444","article-title":"Ticagrelor monotherapy versus dual-antiplatelet therapy after PCI: an individual patient-level meta-analysis","volume":"14","author":"Valgimigli","year":"2021","journal-title":"JACC: Cardiovasc Interv"},{"key":"2026080909323061500_bib10","doi-asserted-by":"crossref","first-page":"n1332","DOI":"10.1136\/bmj.n1332","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"key":"2026080909323061500_bib11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080909323061500_bib12","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/CIRCULATIONAHA.116.023952","article-title":"A critical appraisal of aspirin in secondary prevention","volume":"134","author":"Gargiulo","year":"2016","journal-title":"Circulation"},{"key":"2026080909323061500_bib13","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention","volume":"15","author":"Capodanno","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2026080909323061500_bib14","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"key":"2026080909323061500_bib15","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-5683.22.06038-0","article-title":"Duration and kind of","author":"D'ascenzo","year":"2022","journal-title":"Minerva Cardiol Angiol"},{"key":"2026080909323061500_bib16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvad016\/49733343\/pvad016.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/3\/271\/49806041\/pvad016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/3\/271\/49806041\/pvad016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T13:33:33Z","timestamp":1786282413000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/9\/3\/271\/7069319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,3]]},"published-print":{"date-parts":[[2023,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvad016","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4]]},"published":{"date-parts":[[2023,3,3]]}}}